VistaGen Appoints Reid Adler as Chief Legal Officer
02 Maio 2022 - 9:00AM
Business Wire
VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen) a late
clinical-stage, central nervous system (CNS)-focused
biopharmaceutical company aiming to transform the treatment
landscape for individuals living with anxiety, depression and other
CNS disorders, today announced the appointment of Reid Adler as its
Chief Legal Officer. Adler will oversee VistaGen's legal affairs
and provide strategic guidance to its Executive Team and Board of
Directors.
“We are excited to welcome Reid to VistaGen’s Executive Team,”
said Shawn Singh, Chief Executive Officer. “He is a visionary,
trusted advisor and proven leader who brings deep legal experience
across numerous domains as well a passion for helping patients and
creating change. We look forward to his perspectives and insights
as we continue to grow our business. We are excited about our
potential to positively impact millions of people suffering from
anxiety and depression disorders, and we are confident Reid is the
right legal expert to guide us on our important work.”
“It's a privilege to join the VistaGen leadership team after
supporting the company’s efforts as outside counsel,” stated Reid
Adler. “The pandemic continues to remind us how many individuals
suffer with paralyzing mental health challenges and the critical
need for supportive medications. I look forward to joining the team
and using my legal expertise to help advance the company’s
continued success.”
With a legal career spanning more than three decades, Adler
joins VistaGen from the law firm Capital Technology Law Group,
where he served as the legal counsel for several technology and
life science businesses and not-for-profits, over the past decade.
Adler has been at the forefront of strategic planning, developing
programs and policies for various types of organizations, providing
governance advice to senior management, negotiating complex
technology transactions and the strategic management of
intellectual property assets. His career includes experience as a
senior partner at two international law firms, Morrison &
Foerster and Morgan Lewis, as well as general counsel to the
pioneering J. Craig Venter Institute for genomics. He has also
consulted with several multinational pharmaceutical companies on
product exclusivity and for the Coalition for Epidemic Preparedness
Innovations on legal and business development aspects of
vaccines.
Adler was the founding director of the National Institutes of
Health (NIH) Office of Technology Transfer, where he built a team
of over 40 people to evaluate the translation of research projects
into health care products. He played a key role at the NIH in
developing policies and model agreements, research integrity
guidelines and the Uniform Biological Material Transfer Agreement,
currently used by hundreds of organizations worldwide.
Adler received a Bachelor of Science degree from University of
Maryland, College Park and a Juris Doctor degree from George
Washington University.
About VistaGen
VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused
biopharmaceutical company striving to transform the treatment
landscape for individuals living with anxiety, depression and other
CNS disorders. The Company is advancing therapeutics with the
potential to be faster-acting, and with fewer side effects and
safety concerns, than those that are currently available.
VistaGen’s clinical-stage candidates are targeting multiple forms
of anxiety and depression. They belong to a new class of drugs
known as pherines, which are odorless, tasteless, neuroactive
steroids that bind to distinct receptors on chemosensory neurons in
the nasal passages and can impact the limbic amygdala without
systemic uptake or direct activity on CNS neurons in the brain.
VistaGen’s lead candidate, PH94B, is a nasally administered spray
currently in multiple Phase 3 trials in the U.S., with results
anticipated in 2022. Should ongoing Phase 3 studies be successful,
PH94B has the potential to be the first FDA-approved, fast-acting,
acute treatment of anxiety for adults with social anxiety disorder.
With an experienced leadership team, VistaGen is passionate about
transforming mental health care and redefining what is possible in
the treatment of anxiety and depression. Connect at
www.VistaGen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220502005325/en/
Media Nate Hitchings SKDK Email:
nhitchings@skdknick.com
Investors Mark Flather Vice President, Investor
Relations, VistaGen Therapeutics Phone: (650) 577-3617 Email:
mflather@vistagen.com
VistaGen Therapeutics (NASDAQ:VTGN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
VistaGen Therapeutics (NASDAQ:VTGN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024